Information:
Fel:
ID
46172
Beskrivning
Principal Investigator: Howard McLeod, Moffitt Cancer Center, Tampa, FL, USA MeSH: Prostatic Neoplasms,Neutropenia https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001002 The Cancer and Leukemia Group B (CALGB) 90401 trial compared docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer. A genome-wide association study using clinical outcomes and toxicities was conducted on the basis of data from CALGB patients who provided consent for pharmacogenomic studies and usable DNA
Länk
Nyckelord
Versioner (2)
- 2023-11-09 2023-11-09 - Simon Heim
- 2025-01-29 2025-01-29 - Akane Nishihara
Rättsinnehavare
Howard McLeod, Moffitt Cancer Center, Tampa, FL, USA
Uppladdad den
29 januari 2025
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
dbGaP phs001002 Metastatic Castration-resistant Prostate Cancer GWAS
Subject ID, sample ID, sample source, source sample ID, and sample use variable obtained from participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
- StudyEvent: dbGaP phs001002 Metastatic Castration-resistant Prostate Cancer GWAS
- Eligibility Criteria
- Subject ID, consent group, subject source, source subject ID, and affection status of participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
- Subject ID, sample ID, sample source, source sample ID, and sample use variable obtained from participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
- Subject ID, neuropathy, neutropenia, genetic European status, age, sex, hemoglobin, palliative radiation, specimen(s) limitations, blood specimen, ethnicity, race, medical history of participant smoking and venous and arterial thromboembolism, arterial and or venous thromboembolism, BMI, diabetes, gastrointestinal tract, hemorrhage, Khorana risk status, anti-platelet or anti-coagulant use, and treatment arm assignment of participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
- Sample ID, body site where sample was obtained, analyte type, tumor status of sample, histological type, and genotyping center of participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
Similar models
Subject ID, sample ID, sample source, source sample ID, and sample use variable obtained from participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
- StudyEvent: dbGaP phs001002 Metastatic Castration-resistant Prostate Cancer GWAS
- Eligibility Criteria
- Subject ID, consent group, subject source, source subject ID, and affection status of participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
- Subject ID, sample ID, sample source, source sample ID, and sample use variable obtained from participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
- Subject ID, neuropathy, neutropenia, genetic European status, age, sex, hemoglobin, palliative radiation, specimen(s) limitations, blood specimen, ethnicity, race, medical history of participant smoking and venous and arterial thromboembolism, arterial and or venous thromboembolism, BMI, diabetes, gastrointestinal tract, hemorrhage, Khorana risk status, anti-platelet or anti-coagulant use, and treatment arm assignment of participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
- Sample ID, body site where sample was obtained, analyte type, tumor status of sample, histological type, and genotyping center of participants with metastatic castration-resistant prostate cancer and involved in the "A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer" project.
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
SUBJECT_ID
Item
Subject ID
string
C2348585 (UMLS CUI [1,1])
SAMPLE_ID
Item
Sample ID
string
C1299222 (UMLS CUI [1,1])
SAMPLE_SOURCE
Item
Source repository where samples originate
string
C3847505 (UMLS CUI [1,1])
C0449416 (UMLS CUI [1,2])
C2347026 (UMLS CUI [1,3])
C0449416 (UMLS CUI [1,2])
C2347026 (UMLS CUI [1,3])
SOURCE_SAMPLE_ID
Item
Sample ID used in the Source Repository
string
C1299222 (UMLS CUI [1,1])
C3847505 (UMLS CUI [1,2])
C0449416 (UMLS CUI [1,3])
C3847505 (UMLS CUI [1,2])
C0449416 (UMLS CUI [1,3])
CL Item
SNP genotypes obtained using standard or custom microarrays (Array_SNP)
C2347026 (UMLS CUI [1,1])
C0042153 (UMLS CUI [1,2])
C0752046 (UMLS CUI [1,3])
C1449575 (UMLS CUI [1,4])
C0042153 (UMLS CUI [1,2])
C0752046 (UMLS CUI [1,3])
C1449575 (UMLS CUI [1,4])
Inga kommentarer